GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Infant Bacterial Therapeutics AB (GREY:IFTBF) » Definitions » Forward Dividend Yield %

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Forward Dividend Yield % : 0.00% (As of Jun. 19, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Infant Bacterial Therapeutics AB Forward Dividend Yield %?

As of today (2024-06-19), the Forward Annual Dividend Yield of Infant Bacterial Therapeutics AB is 0.00%.

As of today (2024-06-19), the Trailing Annual Dividend Yield of Infant Bacterial Therapeutics AB is 0.00%.

IFTBF's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.69
* Ranked among companies with meaningful Forward Dividend Yield % only.

Infant Bacterial Therapeutics AB's Dividends per Share for the three months ended in Mar. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Infant Bacterial Therapeutics AB's Forward Dividend Yield %

For the Biotechnology subindustry, Infant Bacterial Therapeutics AB's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Infant Bacterial Therapeutics AB's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Infant Bacterial Therapeutics AB's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Infant Bacterial Therapeutics AB's Forward Dividend Yield % falls into.



Infant Bacterial Therapeutics AB Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Infant Bacterial Therapeutics AB  (GREY:IFTBF) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Infant Bacterial Therapeutics AB Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Infant Bacterial Therapeutics AB's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Business Description

Traded in Other Exchanges
Address
Bryggargatan 10, Stockholm, SWE, 111 21
Infant Bacterial Therapeutics AB is a pharmaceutical company that develops drugs influencing the human infant microbiome, and thereby prevents or treats rare diseases affecting premature infants. It is currently developing its lead drug candidate IBP-9414, to prevent NEC and improve feeding tolerance in premature infants. IBP-9414 contains the active compound Lactobacillus reuteri, which is a human bacterial strain naturally present in breast milk. IBT is further pursuing a second rare disease program IBP-1016 for the treatment of an unmet medical need in gastroschisis, a severe disease in infants.

Infant Bacterial Therapeutics AB (Infant Bacterial Therapeutics AB) Headlines

No Headlines